Hanmi Pharmaceuticals Co Ltd (Hanmi Pharmaceuticals) manufactures and sells medicines and pharmaceutical raw materials. The company classifies its products into over-the-counter (OTC) and ethical pharmaceuticals. The company offers global contract development and manufacturing organization (CDMO) services covering the entire pharmaceutical lifecycle, from supplying critical raw materials, such as chemical active pharmaceutical ingredients (APIs), peptides, polyethylene glycol (PEG), lipids, and mRNA cap analogs, to developing and producing chemically synthesized and biopharmaceutical products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Hanmi Pharmaceuticals focuses its R&D on high unmet medical needs in obesity, metabolism, oncology, and rare diseases, leveraging long-acting biologics, bispecific antibodies, and new modalities supported by its LAPSCOVERY technology platform. The company's R&D is run through six units: the Hanmi R&D Center (new drugs/new modalities), HQ Global Business & New Product Development (clinical, regulatory, licensing), Pharmaceutical Research Center (combination drugs and formulations), Bioprocess Development Team (recombinant proteins), Hanmi Fine Chemical R&D Center (API process development incl. peptides/PEG/mRNA raw materials), and Beijing Hanmi R&D Center (bispecifics via PENTAMBODY). The company holds 1,780 patents and advances a pipeline that includes efpeglenatide (MSD) and efocipegtrutide in obesity/metabolism; belvarafenib (Genentech/Roche), tuspetinib (Aptose), and BH2950 (Innovent) in oncology; and sonefpeglutide (Eli Lilly) and efpegsomatropin in rare diseases, alongside marketed/late-stage assets such as ROLVEDON, ROLONTIS (Assertio) and ORAXOL (Health Hope Pharma). In FY2025, the company spent KRW195,834.353 million on R&D, which as a percentage of revenue, stood at 12.7% and grew 9.5% YoY.